Epitope prediction is a critical component of modern vaccine design, helping researchers identify the specific parts of a pathogen’s proteins that can trigger a strong immune response. By analyzing the structure of antigens, computational tools are employed to predict which epitopes—small fragments of the antigen recognized by immune cells—are most likely to induce immunity. This is especially important for designing vaccines for pathogens that have high variability, like influenza or HIV. Accurate epitope prediction can significantly improve the efficacy of a vaccine, ensuring that it targets the most relevant components of a pathogen. This strategy not only enhances the immune response but also reduces the chances of the pathogen escaping immune detection due to mutations. As vaccine technology evolves, epitope prediction plays an increasingly important role in designing vaccines that provide broad protection, are more cost-effective, and can be rapidly adapted to emerging infectious diseases.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey